This prospective study was conducted to evaluate the efficacy and safety of hypofractionated radiotherapy combined with granulocyte-macrophage colony-stimulating factor, pomalidomide and glofitamab in patients with newly diagnosed primary central nervous system diffuse large B-cell lymphoma.
Written informed consent must be obtained before any study-related procedures.
Age ≥18 years, regardless of sex, with an expected survival time >3 months.
Histologically confirmed diffuse large B-cell lymphoma (DLBCL).
Newly diagnosed patients with primary central nervous system diffuse large B-cell lymphoma (PCNSL).
Loss of CD20 expression in B-cell non-Hodgkin lymphoma.
HBV DNA >2,000 IU/mL or >10⁴ copies/mL without willingness to receive regular antiviral therapy;
HCV RNA >10³ copies/mL;
Concurrent positivity for HBsAg and anti-HCV antibody.